Summary

The global meningitis vaccines market is steadily advancing as healthcare systems worldwide intensify efforts to combat infectious diseases through preventive immunization. Meningitis remains a critical public health concern due to its rapid onset, high morbidity, and potential fatality if left untreated. Vaccination has emerged as the most effective preventive strategy, leading to increased global focus on immunization coverage and vaccine accessibility. In line with this trend, the meningitis vaccines market is projected to reach 4.3 bn in 2026 and further expand to 6.2 bn by 2033, registering a compound annual growth rate of 5.30% over the forecast period.

Market Insights

The market is evolving with strong contributions from pharmaceutical giants and regional vaccine manufacturers aiming to enhance product portfolios and expand global reach. Advances in vaccine technologies, particularly conjugate and recombinant formulations, have significantly improved protection against various meningococcal serogroups. There is a growing shift toward multivalent vaccines that offer broader coverage, addressing the need for comprehensive immunization strategies. Additionally, increased government funding and support from global health organizations are strengthening immunization frameworks, especially in developing regions. Improvements in storage, logistics, and distribution systems are also ensuring wider vaccine penetration across both urban and rural settings.

Drivers

The growth of the meningitis vaccines market is largely driven by the rising incidence of bacterial and viral meningitis infections globally. Public health awareness campaigns highlighting the importance of early vaccination are significantly influencing adoption rates. Government-led immunization programs, particularly those targeting infants, children, and adolescents, are further fueling demand. Continuous investments in research and development aimed at improving vaccine safety, efficacy, and duration of protection are also contributing to market expansion. In addition, the increasing focus on outbreak prevention and disease surveillance is encouraging the adoption of routine vaccination schedules across various regions.

Business Opportunity

The meningitis vaccines market presents substantial opportunities for growth and innovation. The development of advanced multivalent and next-generation vaccines capable of targeting multiple strains simultaneously is expected to unlock new revenue streams. Emerging markets offer considerable growth potential due to expanding healthcare infrastructure and rising government initiatives to improve vaccination coverage. Strategic collaborations between global health agencies and vaccine manufacturers are enabling cost-effective production and distribution. Furthermore, the integration of biotechnology advancements, including recombinant DNA technologies, is paving the way for more efficient and scalable vaccine development. The increasing emphasis on global health preparedness is also expected to sustain long-term demand for meningitis vaccines.

Region Analysis

North America continues to dominate the meningitis vaccines market due to well-established healthcare systems, high vaccination awareness, and strong regulatory support. The region benefits from the presence of leading pharmaceutical companies and continuous advancements in vaccine technologies. Europe follows closely, supported by structured immunization programs and widespread adoption of preventive healthcare practices.

Asia Pacific is anticipated to register significant growth during the forecast period, driven by large population bases, increasing healthcare investments, and expanding immunization campaigns. Countries such as India and China are actively working to enhance vaccine accessibility and strengthen public health infrastructure. Latin America is also experiencing steady growth, supported by improving healthcare services and rising awareness regarding infectious disease prevention. Meanwhile, the Middle East and Africa region holds strong potential, particularly due to the high prevalence of meningitis in certain areas and the implementation of large-scale vaccination initiatives led by international health organizations.

Key Players

• GlaxoSmithKline plc (GSK)

• Pfizer Inc.

• Sanofi S.A. (Sanofi Pasteur)

• Merck & Co., Inc.

• Serum Institute of India Pvt. Ltd.

• CSL Limited (Seqirus)

• Bharat Biotech International Ltd.

• Walvax Biotechnology Co., Ltd.

• Hualan Biological Engineering Inc.

• Chongqing Zhifei Biological Products Co., Ltd.

• Bio-Manguinhos / Fiocruz

• China National Biotec Group (CNBG)

• Bio-Med Pvt. Limited

• Panacea Biotec Ltd.

• Biological E. Limited

Segmentation

By Technology / Formulation

• Conjugate Vaccines

• Polysaccharide Vaccines

• Protein / Recombinant Subunit Vaccines

By Targeted Serotypes (for Meningococcal)

• Serogroup A vaccines

• Serogroup B vaccines

• Serogroup C vaccines

• Serogroup W-135 / Y vaccines

• Combination Pentavalent / Multivalent (A/B/C/W/Y)

By Age Group

• Infants (0–2 years)

• Children & Adolescents (2–18 years)

• Adults (18+ years)

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Government Immunization Programs / Public Health Agencies

• Online Pharmacies & Others

By Geography

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Meningitis Vaccines Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2026
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Five Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2025-2033
2.9.2. Price Impact Factors
3. Global Meningitis Vaccines Market Outlook, 2020-2033
3.1. Global Meningitis Vaccines Market Outlook, by Technology / Formulation, Value (US$ Bn), 2020-2033
3.1.1. Conjugate Vaccines
3.1.2. Polysaccharide Vaccines
3.1.3. Polysaccharide Vaccines
3.2. Global Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), Value (US$ Bn), 2020-2033
3.2.1. Serogroup A vaccines
3.2.2. Serogroup B vaccines
3.2.3. Serogroup C vaccines
3.2.4. Serogroup W-135 / Y vaccines
3.2.5. Combination Pentavalent / Multivalent (A/B/C/W/Y)
3.3. Global Meningitis Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
3.3.1. Infants (0–2 years)
3.3.2. Children & Adolescents (2–18 years)
3.3.3. Adults (18+ years)
3.4. Global Meningitis Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
3.4.1. Hospital Pharmacies
3.4.2. Retail Pharmacies
3.4.3. Government Immunization Programs / Public Health Agencies
3.4.4. Online Pharmacies & Others
3.5. Global Meningitis Vaccines Market Outlook, by Region, Value (US$ Bn), 2020-2033
3.5.1. North America
3.5.2. Europe
3.5.3. Asia Pacific
3.5.4. Latin America
3.5.5. Middle East & Africa
4. North America Meningitis Vaccines Market Outlook, 2020-2033
4.1. North America Meningitis Vaccines Market Outlook, by Technology / Formulation, Value (US$ Bn), 2020-2033
4.1.1. Conjugate Vaccines
4.1.2. Polysaccharide Vaccines
4.1.3. Polysaccharide Vaccines
4.2. North America Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), Value (US$ Bn), 2020-2033
4.2.1. Serogroup A vaccines
4.2.2. Serogroup B vaccines
4.2.3. Serogroup C vaccines
4.2.4. Serogroup W-135 / Y vaccines
4.2.5. Combination Pentavalent / Multivalent (A/B/C/W/Y)
4.3. North America Meningitis Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
4.3.1. Infants (0–2 years)
4.3.2. Children & Adolescents (2–18 years)
4.3.3. Adults (18+ years)
4.4. North America Meningitis Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
4.4.1. Hospital Pharmacies
4.4.2. Retail Pharmacies
4.4.3. Government Immunization Programs / Public Health Agencies
4.4.4. Online Pharmacies & Others
4.5. North America Meningitis Vaccines Market Outlook, by Country, Value (US$ Bn), 2020-2033
4.5.1. U.S. Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
4.5.2. U.S. Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
4.5.3. U.S. Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
4.5.4. U.S. Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
4.5.5. Canada Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
4.5.6. Canada Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
4.5.7. Canada Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
4.5.8. Canada Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
4.6. BPS Analysis/Market Attractiveness Analysis
5. Europe Meningitis Vaccines Market Outlook, 2020-2033
5.1. Europe Meningitis Vaccines Market Outlook, by Technology / Formulation, Value (US$ Bn), 2020-2033
5.1.1. Conjugate Vaccines
5.1.2. Polysaccharide Vaccines
5.1.3. Polysaccharide Vaccines
5.2. Europe Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), Value (US$ Bn), 2020-2033
5.2.1. Serogroup A vaccines
5.2.2. Serogroup B vaccines
5.2.3. Serogroup C vaccines
5.2.4. Serogroup W-135 / Y vaccines
5.2.5. Combination Pentavalent / Multivalent (A/B/C/W/Y)
5.3. Europe Meningitis Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
5.3.1. Infants (0–2 years)
5.3.2. Children & Adolescents (2–18 years)
5.3.3. Adults (18+ years)
5.4. Europe Meningitis Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
5.4.1. Hospital Pharmacies
5.4.2. Retail Pharmacies
5.4.3. Government Immunization Programs / Public Health Agencies
5.4.4. Online Pharmacies & Others
5.5. Europe Meningitis Vaccines Market Outlook, by Country, Value (US$ Bn), 2020-2033
5.5.1. Germany Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
5.5.2. Germany Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
5.5.3. Germany Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
5.5.4. Germany Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
5.5.5. Italy Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
5.5.6. Italy Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
5.5.7. Italy Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
5.5.8. Italy Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
5.5.9. France Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
5.5.10. France Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
5.5.11. France Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
5.5.12. France Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
5.5.13. U.K. Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
5.5.14. U.K. Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
5.5.15. U.K. Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
5.5.16. U.K. Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
5.5.17. Spain Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
5.5.18. Spain Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
5.5.19. Spain Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
5.5.20. Spain Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
5.5.21. Russia Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
5.5.22. Russia Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
5.5.23. Russia Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
5.5.24. Russia Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
5.5.25. Rest of Europe Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
5.5.26. Rest of Europe Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
5.5.27. Rest of Europe Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
5.5.28. Rest of Europe Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
5.6. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Meningitis Vaccines Market Outlook, 2020-2033
6.1. Asia Pacific Meningitis Vaccines Market Outlook, by Technology / Formulation, Value (US$ Bn), 2020-2033
6.1.1. Conjugate Vaccines
6.1.2. Polysaccharide Vaccines
6.1.3. Polysaccharide Vaccines
6.2. Asia Pacific Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), Value (US$ Bn), 2020-2033
6.2.1. Serogroup A vaccines
6.2.2. Serogroup B vaccines
6.2.3. Serogroup C vaccines
6.2.4. Serogroup W-135 / Y vaccines
6.2.5. Combination Pentavalent / Multivalent (A/B/C/W/Y)
6.3. Asia Pacific Meningitis Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
6.3.1. Infants (0–2 years)
6.3.2. Children & Adolescents (2–18 years)
6.3.3. Adults (18+ years)
6.4. Asia Pacific Meningitis Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
6.4.1. Hospital Pharmacies
6.4.2. Retail Pharmacies
6.4.3. Government Immunization Programs / Public Health Agencies
6.4.4. Online Pharmacies & Others
6.5. Asia Pacific Meningitis Vaccines Market Outlook, by Country, Value (US$ Bn), 2020-2033
6.5.1. China Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
6.5.2. China Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
6.5.3. China Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
6.5.4. China Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
6.5.5. Japan Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
6.5.6. Japan Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
6.5.7. Japan Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
6.5.8. Japan Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
6.5.9. South Korea Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
6.5.10. South Korea Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
6.5.11. South Korea Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
6.5.12. South Korea Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
6.5.13. India Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
6.5.14. India Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
6.5.15. India Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
6.5.16. India Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
6.5.17. Southeast Asia Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
6.5.18. Southeast Asia Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
6.5.19. Southeast Asia Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
6.5.20. Southeast Asia Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
6.5.21. Rest of SAO Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
6.5.22. Rest of SAO Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
6.5.23. Rest of SAO Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
6.5.24. Rest of SAO Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
6.6. BPS Analysis/Market Attractiveness Analysis
7. Latin America Meningitis Vaccines Market Outlook, 2020-2033
7.1. Latin America Meningitis Vaccines Market Outlook, by Technology / Formulation, Value (US$ Bn), 2020-2033
7.1.1. Conjugate Vaccines
7.1.2. Polysaccharide Vaccines
7.1.3. Polysaccharide Vaccines
7.2. Latin America Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), Value (US$ Bn), 2020-2033
7.2.1. Serogroup A vaccines
7.2.2. Serogroup B vaccines
7.2.3. Serogroup C vaccines
7.2.4. Serogroup W-135 / Y vaccines
7.2.5. Combination Pentavalent / Multivalent (A/B/C/W/Y)
7.3. Latin America Meningitis Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
7.3.1. Infants (0–2 years)
7.3.2. Children & Adolescents (2–18 years)
7.3.3. Adults (18+ years)
7.4. Latin America Meningitis Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
7.4.1. Hospital Pharmacies
7.4.2. Retail Pharmacies
7.4.3. Government Immunization Programs / Public Health Agencies
7.4.4. Online Pharmacies & Others
7.5. Latin America Meningitis Vaccines Market Outlook, by Country, Value (US$ Bn), 2020-2033
7.5.1. Brazil Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
7.5.2. Brazil Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
7.5.3. Brazil Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
7.5.4. Brazil Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
7.5.5. Mexico Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
7.5.6. Mexico Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
7.5.7. Mexico Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
7.5.8. Mexico Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
7.5.9. Argentina Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
7.5.10. Argentina Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
7.5.11. Argentina Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
7.5.12. Argentina Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
7.5.13. Rest of LATAM Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
7.5.14. Rest of LATAM Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
7.5.15. Rest of LATAM Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
7.5.16. Rest of LATAM Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
7.6. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Meningitis Vaccines Market Outlook, 2020-2033
8.1. Middle East & Africa Meningitis Vaccines Market Outlook, by Technology / Formulation, Value (US$ Bn), 2020-2033
8.1.1. Conjugate Vaccines
8.1.2. Polysaccharide Vaccines
8.1.3. Polysaccharide Vaccines
8.2. Middle East & Africa Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), Value (US$ Bn), 2020-2033
8.2.1. Serogroup A vaccines
8.2.2. Serogroup B vaccines
8.2.3. Serogroup C vaccines
8.2.4. Serogroup W-135 / Y vaccines
8.2.5. Combination Pentavalent / Multivalent (A/B/C/W/Y)
8.3. Middle East & Africa Meningitis Vaccines Market Outlook, by Age Group, Value (US$ Bn), 2020-2033
8.3.1. Infants (0–2 years)
8.3.2. Children & Adolescents (2–18 years)
8.3.3. Adults (18+ years)
8.4. Middle East & Africa Meningitis Vaccines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies
8.4.3. Government Immunization Programs / Public Health Agencies
8.4.4. Online Pharmacies & Others
8.5. Middle East & Africa Meningitis Vaccines Market Outlook, by Country, Value (US$ Bn), 2020-2033
8.5.1. GCC Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
8.5.2. GCC Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
8.5.3. GCC Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
8.5.4. GCC Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
8.5.5. South Africa Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
8.5.6. South Africa Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
8.5.7. South Africa Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
8.5.8. South Africa Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
8.5.9. Egypt Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
8.5.10. Egypt Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
8.5.11. Egypt Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
8.5.12. Egypt Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
8.5.13. Nigeria Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
8.5.14. Nigeria Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
8.5.15. Nigeria Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
8.5.16. Nigeria Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
8.5.17. Rest of Middle East Meningitis Vaccines Market Outlook, by Technology / Formulation, 2020-2033
8.5.18. Rest of Middle East Meningitis Vaccines Market Outlook, by Targeted Serotypes (for Meningococcal), 2020-2033
8.5.19. Rest of Middle East Meningitis Vaccines Market Outlook, by Age Group, 2020-2033
8.5.20. Rest of Middle East Meningitis Vaccines Market Outlook, by Distribution Channel, 2020-2033
8.6. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. GlaxoSmithKline plc (GSK)
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. Pfizer Inc.
9.4.3. Sanofi S.A. (Sanofi Pasteur)
9.4.4. Merck & Co., Inc.
9.4.5. Serum Institute of India Pvt. Ltd.
9.4.6. CSL Limited (Seqirus)
9.4.7. Bharat Biotech International Ltd.
9.4.8. Walvax Biotechnology Co., Ltd.
9.4.9. Hualan Biological Engineering Inc.
9.4.10. Chongqing Zhifei Biological Products Co., Ltd.
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations